Abstract 3252
Background
Immune checkpoint inhibitors (ICI) have improved clinical outcome for many patients with advanced cutaneous malignant melanoma (CMM) during the last decade. The magnitude and duration of response vary considerably between patients. Predictive biomarkers to identify patients that will benefit from treatment can increase efficacy, diminish side effects and costs. Our aim is to identify predictive biomarkers in tumors samples from patients with advanced CMM receiving ICI.
Methods
Patients with advanced CMM at Karolinska University Hospital, Stockholm, starting therapy with ICI were invited to participate in our study. After signing informed consent a pre-treatment fine needle or core biopsy was taken from an accessible metastasis. RNA was extracted to perform targeted RNA sequencing using the Ion AmpliSeq Transcriptome Human Gene Expression Kit for RefSeq genes. Partek Genomics Suite® software was applied to find differentially expressed genes and correlate the data with therapy response and progression free survival (PFS).
Results
Nineteen patients were included between September2013 and August2017, 8 female and 11 male. The median age was 70 years old (range 49 – 84). All patients had metastatic disease (13 M1c, 4 M1b, 2 M1a). ICI was first-line treatment for 16 patients. Nivolumab or pembrolizumab was given to 17 patients and two received ipilimumab. Five patients had partial response, 3 stable disease and 7 complete response whereas 4 had progressive diasease. Median PFS was 10 months (range 1,2 – 62 months, 6 patients still responding). High expression of a subset of genes playing a role for DNA replication, genes involved in chromatin remodeling and cell cycle were significantly associated with shorter PFS. The correlation between low expression of interferon gamma signature genes and poorer treatment outcome was confirmed in our study.
Conclusions
Our findings suggest that genes involved in the regulation of DNA replication, chromatin remodeling and cell cycle may influence the long-term response to ICI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University Hospital and Karolinska Institute.
Funding
The Swedish Cancer Society, the Cancer Research Funds of Radiumhemmet and Knut and Alice Wallenberg foundation. We aknowledge support of the Science for Life Laboratory, National Genomics Infrastructure (NGI)/Uppsala, Genome Center and UPPMAX for providing assistance in massive parallel sequencing and computational infrastructure (work funded by RFI/VR and Scilife, Sweden).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract